News
Leaps by Bayer Announces One of the Largest Global Surveys of Society’s Attitudes Toward Breakthrough Technologies
As leaders gather for the World Economic Forum Annual Meeting 2025 in Davos, Leaps by Bayer, the impact investing arm of Bayer, and Boston Consulting Group (BCG) announced the launch of one of the
EQS-News: Alzchem Group AG: Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 - 5th Interim Report
EQS-News: Alzchem Group AG: Disclosure according to Article 5 of the EU Regulation 596/2014 and Article 2 Section (1) of the Delegated EU Regulation 2016/1052 - 5th Interim Report
EQS-News: SFC Energy AG receives new follow-up order from BauWatch – delivery of EFOY Pro fuel cells and refurbishment programme with a volume of several million Euro
EQS-News: SFC Energy AG receives new follow-up order from BauWatch – delivery of EFOY Pro fuel cells and refurbishment programme with a volume of several million Euro
EQS-News: DATAGROUP introduces new generation of the CORBOX
EQS-News: DATAGROUP introduces new generation of the CORBOX
EQS-News: Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
EQS-News: Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
EQS-News: FRIWO AG reorganizes its Executive Board and completes generational transition
EQS-News: FRIWO AG reorganizes its Executive Board and completes generational transition
Alzchem Group AG: Utilization of surplus hydrogen: Alzchem replaces natural gas and saves significantly reduces CO₂ emissions
Alzchem Group AG: Utilization of surplus hydrogen: Alzchem replaces natural gas and saves significantly reduces CO₂ emissions
EQS-Adhoc: ACCENTRO and bondholders agreed on extension of current bridge notes and an additional bridge funding as part of the ongoing restructuring negotiations
EQS-Adhoc: ACCENTRO and bondholders agreed on extension of current bridge notes and an additional bridge funding as part of the ongoing restructuring negotiations
EQS-News: USU Secures New US Customer for Software Asset Management
EQS-News: USU Secures New US Customer for Software Asset Management
EQS-Adhoc: MBB beats its 2024 guidance with revenues of €1.06 billion at an EBITDA margin of more than 13% based on preliminary figures and announces management changes
EQS-Adhoc: MBB beats its 2024 guidance with revenues of €1.06 billion at an EBITDA margin of more than 13% based on preliminary figures and announces management changes
EQS-Adhoc: Verbio SE: Verbio reduces EBITDA forecast for 2024/25; expectation of net financial debt of max. EUR 190 million unchanged
EQS-Adhoc: Verbio SE: Verbio reduces EBITDA forecast for 2024/25; expectation of net financial debt of max. EUR 190 million unchanged
EQS-News: Mynaric Announces Receipt of Deficiency Letters from Nasdaq
EQS-News: Mynaric Announces Receipt of Deficiency Letters from Nasdaq
EQS-News: Heliad: Nelly raises EUR 50m in Series B funding to revolutionize financial operations in healthcare
EQS-News: Heliad: Nelly raises EUR 50m in Series B funding to revolutionize financial operations in healthcare
EQS-News: Allane Mobility Group electrifies fleet of major customer and sets standards for sustainable mobility
EQS-News: Allane Mobility Group electrifies fleet of major customer and sets standards for sustainable mobility
EQS-News: Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects
EQS-News: Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects
EQS-News: Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
EQS-News: Formycon and Fresenius Kabi announce MHRA approval for FYB202/Otulfi® (ustekinumab), a biosimilar to Stelara®
EQS-Adhoc: Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
EQS-Adhoc: Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
Learning through laughing with RiC.today from January 15 on simpliTV
Learning through laughing with RiC.today from January 15 on simpliTV
EQS-News: Starting Signal for USU Digital Consulting: Shaping the Future and Driving Digitalization Forward
EQS-News: Starting Signal for USU Digital Consulting: Shaping the Future and Driving Digitalization Forward
EQS-Adhoc: STEICO SE: unaudited business figures for 2024: revenue of € 376.3 million, EBIT of € 36.1 million
EQS-Adhoc: STEICO SE: unaudited business figures for 2024: revenue of € 376.3 million, EBIT of € 36.1 million
EQS-Adhoc: infas Holding Aktiengesellschaft: infas Holding Aktiengesellschaft: Expansion of management board and expects changes in the supervisory board
EQS-Adhoc: infas Holding Aktiengesellschaft: infas Holding Aktiengesellschaft: Expansion of management board and expects changes in the supervisory board
Swiss companies confirm medium-term revenue targets at Baader Helvea Swiss Equities Conference 2025
Swiss companies confirm medium-term revenue targets at Baader Helvea Swiss Equities Conference 2025
EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
EQS-News: Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
EQS-News: Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel
EQS-News: Teva becomes strategic commercialization partner for Formycon’s biosimilar candidate FYB203 (Eylea®/ aflibercept) in major parts of Europe and Israel